Using small molecules, Abdel-Rahman, L. Zhang, & Moustafa Gabr of Weill Cornell Medicine #Radiology hope to pave the way for drug discovery efforts in the fight against #cancer. Read about their #CancerResearch in SLAS Discovery, a publication of SLAS. pubmed.ncbi.nlm.nih.gov/37121273/

Check out our latest work in RSC Medicinal Chemistry. We report ICOS/ICOSL inhibitors as a novel class of small molecule immunomodulators. Fantastic collaboration with Katarzyna Świderek Excited that this research is now supported by an Elsa U. Pardee Foundation grant pubs.rsc.org/en/content/art…

Excited to share our latest work published in J. Med. Chem. In collaboration with Gerhard Wolber, we used pharmacophore-based screening to identify TIM-3 inhibitors. This work wouldn't have been possible without grant support from American Cancer Society pubs.acs.org/doi/10.1021/ac…

Discovery of ICOS-Targeted Small Molecules Using Pharmacophore-Based Screening (M. T. Gabr et al.) Moustafa Gabr onlinelibrary.wiley.com/doi/10.1002/cm…

Delighted to contribute to this remarkable project! Heartiest congratulations to Shoaib Manzoor & team Jamia Millia Islamia (NAAC A++ Grade Central Univ) & fantastic collaborator Moustafa Gabr from Weill Cornell Medicine 4 bringing this work to fruition after a dedicated 6-year journey! ACS Publications ACSChemNeurosci

🧠 In ACSChemNeurosci, a publication of American Chemical Society, Moustafa Gabr reports new quinolinone hybrids as dual inhibitors of acetylcholinesterase (AChE) and Aβ aggregation, functioning as multitargeted ligands for Alzheimer's disease. pubs.acs.org/doi/10.1021/ac…

📢Read our Newly_Published_Paper "This comprehensive review explores cutting-edge developments in targeting immune #checkpoints, focusing on both #small_molecule- and #peptide-based approaches." 👨‍💻By Moustafa Gabr Moustafa Gabr et al. 🏫Weill Cornell Medicine 📚More: mdpi.com/2626236

📝In 'Bioorganic & Medicinal Chemistry Letters,' the work of S. Abdel-Rahman, L. Calvo-Barreiro, & Moustafa Gabr lays the groundwork for future #cancer drug discovery endeavors, with the goal of developing cyclic peptides targeting the ICOS/ICOSL interaction. sciencedirect.com/science/articl…

The Gabr Lab at Weill Cornell reports 3-oxo-lithocholic acid amidates as potent modulators of the nuclear receptor RORγt Moustafa Gabr pubs.rsc.org/en/content/art…

Introducing Genie 2, our latest protein design model! Genie 2 sets a new state of the art on key design metrics and supports motif scaffolding, including that of multiple motifs with undefined geometric relationships, a feature new to protein diffusion models. (1/5)

Glad to share that our paper on small molecule LAG-3 inhibitors has been selected for a special collection on the Future of Medicinal Chemistry. We’re proud to be the first to target LAG-3 with small molecules and thankful to the Elsa U. Pardee Foundation for their support

🏥 Read "Structure-Based Rational Design of Constrained Peptides as TIM-3 Inhibitors," recent work from Somaya Abdel-Rahman & Moustafa Gabr in ACS Med Chem Lett, a publication of American Chemical Society, here 👉 tinyurl.com/bdfc4rh5

Happy to see our recent publication in ACS Medicinal Chemistry Letters highlighted on the journal cover! Details on this novel class of TIM-3-targeted peptides as immunomodulators can be found here: pubs.acs.org/doi/10.1021/ac…

🚨Job alert🚨Thrilled to share that the Gabr Lab received FIVE R01 grants for small molecule immunomodulators research. We are hiring postdocs with expertise in medicinal chemistry, neuropharmacology, or protein biochemistry. Applicants can send CVs to [email protected]

📝 Read "Discovery of ICOS-targeted small molecules using affinity selection mass spectrometry screening," a bioRxiv by Longfei Zhang, Laura Calvo-Barreiro, Moustafa Gabr, & co. 👉 tinyurl.com/y4y3hnzb

Our new paper published today in nature! Study Uncovers Mutations and DNA Structures Driving Bladder Cancer news.weill.cornell.edu/news/2024/10/s…

Excellent opportunity to join the Faltas lab

🏥 Read "Virtual screening: hope, hype, and the fine line in between" by Hossam Nada, Nicholas Meanwell, & Moustafa Gabr in 'Expert Opinion on Drug Discovery' 👉 tinyurl.com/c5ye4wbp

HTS-Oracle: A Retrainable AI Platform for High-Confidence Hit Identification Across Difficult-to-Drug Targets 1. The introduction of HTS-Oracle marks a significant advancement in high-throughput screening (HTS) for drug discovery. This AI platform leverages deep learning to

Designing immunity with cytokines: A logic-based framework for programmable CAR therapies sciencedirect.com/science/articl… Moustafa Gabr Weill Cornell Medicine